Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Assessment of Activity Limitations, a Basis for Understanding the Need for Sickness Certificate and Rehabilitation

NCT05772494 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2023-04-03
Last updated
2026-05-06

Condition(s) studied

Sick Leave

Investigational drug(s) / intervention(s)

Assessment of activity limitations, SDO and DOAControl group

Assessment of activity limitations, SDO and DOA: The assessment is made with two instruments (DOA, SDO), and finally the occupational therapist includes the analysis and summary of activity limitations to the sickness certificate. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave

Control group: All assessments concerning activity limitations are made using usual routines, primarily by the sick-listing physician. For comparative reasons the participant will answer to a sociodemographic questionnaire focusing on work situation and sick leave

Study summary

In Sweden mental disorders have the highest proportion of sickness absence and sickness spells. One cause for this is proposed as the lack of knowledge on which activity limitations that have an impact on the ability to return to work. Further, there is a knowledge gap concerning the effect of which early measures from the health system, assessments and early rehabilitation interventions, that enables return to work. Such early measures have been proposed to have a more multidimensional perspective, than to solely focus on specific tasks during a work situation.

The aim of the current project is to examine the effect of an early assessment of activity limitations, made by occupational therapists within specialized psychiatric care, at the time for the next prolonged sickness certification. The assessment will be included in the sickness certificate, and results will be compared between the intervention group and a control group. The results are calculated for differences on treatment measures, prevalence of questions from the Social Insurance Agency and changes in the patterns for sick leave spells. Further, the prevalence of activity limitations and the sick listed participants assessments of the effect of the intervention will be presented.

The results are expected to lead to more adequate interventions for the individual regarding support to return to work, better routines for assessment and rehabilitation within the health care system, which in turn can facilitate decisions for sickness benefits and further have an impact on the long sick leave spells concerning mental disorders.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * All patients registered at the chosen psychiatric care centers, in need for their second or third sickness certificate within the unit. Exclusion Criteria: * Patients with specific diagnosis belonging to another unit within the psychiatric organization. * Patients assessed as being in an acute vulnerable situation where the planned intervention could negatively influence the situation e.g. having suicidal thoughts, or having such language difficulties that an interpreter is needed (which could complicate the understanding of the meaning of the intervention and cause unnecessary worries).

Primary outcome measure(s)

  • Health care treatments — 6 months after inclusion
    Differences in types of healthcare treatment options between intervention and control group. Comparisons will be made between intervention and control group with regard to registered codes for intervention and codes for professionals responsible for treatment options. Descriptive calculations and comparisons will be made on differences in types of as well as changes in treatment measures within the notified time frame.
  • Changes in sick leave patterns — 6 months after inclusion
    Differences in number of sick leave periods, full-time or part-time or number of sick leave spells between intervention and control group.
  • Number of questions from the Social Insurance Agency (SIA) — 6 months after inclusion
    Differences in number of clarifying questions from SIA between intervention and control group.

Trial sites (1)

FacilityCityRegionStatus
Göteborg University, Institute of Neuroscience and Physiology Gothenburg Sweden
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05772494 on ClinicalTrials.gov ↗ ← All trials in Sweden